ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Bimatoprost Ophthalmic Solution

Also written as “bimatoprost ophthalmic solution 0.03%”, “bimatoprost ophthalmic solution 0.01%” and “Bimatoprost ophthalmic solution 0.01% YSBP”.

Its studies are mostly in Glaucoma, Open-Angle · Hypotrichosis · Alopecia Areata, led by 3 companies.

Drug pageBimatoprost Ophthalmic Solution: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 30, 20099 company-led studies, 2 open or runningNext primary completion: Nov 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie70 open or runningphase 4since Nov 30, 2009Nov 30, 2009none ahead
Amneal Pharmaceuticalsits history only11 open or runningphase 1since Feb 12, 2024Feb 12, 2024none ahead
YS Life Scienceits history only11 open or runningphase 3since Jun 16, 2026Jun 16, 2026Nov 1, 2027phase 3 · NCT07661329

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 30, 2009First study: phase 4 study in Alopecia AreataFirst studyNCT01023841 · 71 enrolled · United States, Brazil
  2. Feb 5, 2010Phase 2 study in Eyelash HypotrichosisNCT01064882 · 104 enrolled · United States
  3. Dec 2, 2010Phase 4 study in Glaucoma, Open-AngleNCT01253902 · 164 enrolled · United States, Canada
  4. Oct 6, 2011Phase 4 study in HypotrichosisNCT01448525 · 88 enrolled · United States
  5. Feb 10, 2012Phase 4 study in Glaucoma, Open-AngleNCT01547598 · 135 enrolled · Canada
  6. Jun 25, 2014Phase 4 study in Facial RhytidesNCT02176356 · 116 enrolled · United States
  7. May 2, 2016Phase 4 study in Glaucoma, Open-AngleNCT02863705 · 118 enrolled · Korea, Republic of

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02863705Glaucoma, Open-Angle · Korea, Republic of4CompletedJul 25, 2018118
NCT02176356Facial Rhytides · United States4CompletedMay 3, 2015116
NCT01547598Glaucoma, Open-Angle · Canada4CompletedJul 2013135
NCT01448525Hypotrichosis · United States4CompletedApr 201288
NCT01253902Glaucoma, Open-Angle · United States, Canada4CompletedOct 2011164
NCT01064882Eyelash Hypotrichosis · United States2CompletedJul 2010104
NCT01023841Alopecia Areata · United States, Brazil4CompletedNov 2, 201271

How it is read

Names in the registry

  • “bimatoprost ophthalmic solution 0.03%”, 4 entries
  • “bimatoprost ophthalmic solution 0.01%”, 2 entries
  • “Bimatoprost ophthalmic solution 0.01% YSBP”, 1 entry
  • “Bimatoprost Ophthalmic Solution, 0.01%”, 1 entry
  • “Bimatoprost ophthalmic solution 0.01%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.